{Brief Introduction}

     Zhejiang Jingxin Pharmaceutical Co., Ltd. is a listed pharmaceutical company, integrating R & D, manufacturing and marketing, ranks top 100 of the chemical pharmaceutical enterprises in China. At the moment, The company has more than 2300 staffs. Five manufacturing bases are under function：formulations in Xinchang, API & intermediate in Shangyu and Guangfeng, TCM in Inner Mongolia and Guangdong ,medical devices and instruments in Shenzhen. Moreover, R&D centers are located in Shanghai Zhangjiang High-Tec Park &America Pennsylvania for advanced drug and API development.

{Products Range&Capacity}

   The company’s products contain drug and medical devices. Drug products line consists of Chemicals, TCM and bio-medicine, the formulations are focused on cardiovascular, digestive and neurological, among which, Simvastatin Tablet is the first finished products exported to UK , and gave the first step for the Chinese formulation exporting to the high-end market, Rosuvastatin Calcium Tablets owns the largest market share in domestic, the TCM “Kangfuxin Solution” won the Gold Prize of “Illness Bane” by Ministry of Health and praised as “ Miraculous Drug” by patients, digestive products Bacillus licheniformis capsules is the bio-medicine of the company. The key API of Quinolone – Levofloxacin ranks No. 1 in the sales all over the world. 

    The main dosage forms of formulation including Tablets, Capsules and Powder for injections, She has a large production capacity, for example 5 billion tablets &capsules per year.

Jingxin Pharm is one of the largest production bases for the API of Quinolones; Jingxin Pharm has its own API source for the finish products,such as Simvastain,Ciprofloxacin Hydrochloride, Levetiracetam ,Sertraline Hydrochloride, Rosuvastatin Calcium and so on, She has the price advantage on the finish products.

    Regarding the medical devices, it is concentrated on the medical display instruments currently, providing full series medical imaging display solution, covers almost all medical imaging application areas, including clinical review, diagnostic, consultation center, digitized surgical room and ultrasound, CT, MRI, DR, DSA, DSI, endoscope etc.

{Perfect Quality Management System}

       Taking the quality concept of “Made our products, by our heart”, Jingxin is in the first group of passing the SFDA GMP of new version. Previously, Jingxin had been certified by the EU GMP in 2006 and successfully passed the 3-years term’s re-inspection ever since. The last inspection was conducted in May, 2015, the new constructed workshop with much larger capacity was certified. Afterwards, the company began the preparation of the US FDA inspection to broaden the market in the near future.

Our products can comply with the current standard of BP,USP,EP,CP.as per clients’ requirements.

{Mergers and Acquisitions}

The company is developing through independent research and development, on the other side, Jingxin is growing via M&A to accelerate the developing pace. In Domestic market, Jingxin acquired a TCM factory in Inner Mongolia in 2007, a bio-medicine company in Beijing in 2011, comprehensive pharmaceutical company in Guangdong Province in 2013 and an advanced medical devices company in 2015; overseas, Jingxin established a joint venture in UK in 2014, invested a medical device company in Israel in 2015, bought the controlling interest of a US pharmaceutical company in 2015.

{Market Distribution}

        There are professional international trade team and international regulatory team in the firm, Jingxin Pharm has rich export experience, developed export business for more than 10 years, and successfully registered lots of products in many countries. The main international markets are Europe, America ,Africa, Southeast

{Direction of the Company}

Based on China, Jingxin Pharm pursues to stretch business to any market in the world, especially high-end markets, and focus on developing and manufacturing high-quality products for the health of human around the word.

Jingxin Pharm is willing to work with oversea clients to start cooperation on the finished drugs by any possible way, such as CRO/CMO/JV/M&A/Joint developing.